All-cause mortality and causes of death in the Swiss Hepatitis

C Cohort Study

3

38

4	
5	Maroussia Roelens ^{1*} , Barbara Bertisch ^{1*} , Darius Moradpour ² , Andreas Cerny ³ , Nasser Semmo ⁴ ,
6	Patrick Schmid ⁵ , Beat Müllhaupt ⁶ , Olivier Clerc ⁷ , David Semela ⁸ , Christoph Junker ⁹ , Francesco
7	Negro ¹⁰ , Olivia Keiser ¹ , for the Swiss Hepatitis C Cohort Study
8	
9	¹ Institute of Global Health, University of Geneva, Geneva, Switzerland
10 11 12	² Division of Gastroenterology and Hepatology, University Hospital Lausanne, Lausanne, Switzerland
13 14	³ Fondazione Epatocentro Ticino, Lugano, Switzerland
15 16	⁴ Department for BioMedical Research, Hepatology, University of Bern, Bern, Switzerland
17 18	⁵ Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen
19 20	⁶ Swiss Hepato-Pancreato-Biliary Center and Department of Gastroenterology and Hepatology, University Hospital, Zürich, Switzerland
21 22 23	⁷ Department of Internal Medicine and Infectious Diseases, Pourtalès Hospital, Neuchâtel, Switzerland
23 24 25	⁸ Division of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
26 27	⁹ Swiss Federal Statistical Office, Section Population Health, Neuchâtel, Switzerland
28 29 30	¹⁰ Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals Geneva, Geneva, Switzerland
31 32 33 34	Corresponding author: Maroussia Roelens, Institute of Global Health, University of Geneva, Campus Biotech, Chemin des Mines 9, 1202 Geneva, Switzerland. Email: maroussia.roelens@unige.ch; Phone: +41 (0) 22 3790869
35	*These authors contributed equally to the current work
36	
37	Keywords: hepatitis C, mortality, risk factors, cohort, Switzerland
20	5204

5.10014: WWG referribt fegotte Shew etables that has not been certified by peer review and should not be used to guide clinical practice.

40 Conflict of interest: none 41 Financial support statement: This work was supported by the Swiss National Science Foundation (grant No. 163878). 42 43 Authors contributions: OK, BB and FN contributed to the design of the study. MR did the data 44 analyses under the supervision of OK and BB. BB reviewed the causes of death. CJ performed 45 the linkage between the SCCS decedents and the SFSO death registry. MR, BB and OK wrote 46 47 the first draft of the paper. All authors contributed to the revision of the initial manuscript. All authors approved the final manuscript. 48

Abstract

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

interventions.

Background & Aims: With the introduction of direct-acting antiviral agents (DAA), mortality rates and causes of death among persons with hepatitis C virus (HCV) infection are likely to change over time. However, the emergence of such trends may be delayed by the relatively slow progression of chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited. Methods: We evaluated changes in causes of death among the Swiss Hepatitis C Cohort Study (SCCS) participants, from 2008 to 2016. We analysed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office (SFSO) death registry. Results: We included 4,700 SCCS participants, of whom 478 died between 2008 and 2016. Linkage to the SFSO death registry substantially improved the information on causes of death (from 42% of deaths with unknown cause to 10% after linkage). Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 p-yrs) and non-liver cancer (2.8/1000 p-yrs), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response (SVR) were less at risk for liver-related mortality than those never treated or treated unsuccessfully. Conclusions: Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons evolved over time. With the progressive widening of guidelines for DAA use, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAA and to design effective

Lay summary: Leading causes of death among persons with hepatitis C virus (HCV) infection in the Swiss Hepatitis C Cohort study evolved over the past years, with an increasing proportion of cancer-related deaths. The positive impact of new potent anti-HCV drugs on mortality among HCV-infected persons is not yet observable, due to both the slow progression of chronic hepatitis C and the progressive relaxation of guidelines for the use of those new drugs.

Background

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

Hepatitis C virus (HCV) infection is a leading cause of liver-related mortality [1, 2], responsible for about 399,000 deaths worldwide in 2016. With the introduction of potent direct-acting antiviral agents (DAA), the risk of morbidity and mortality for HCV infected persons has decreased substantially [3]. It is likely that causes of death are changing over time and with age, since HCV infected people may become increasingly at risk of dying from non-liver-related causes, including non-liver-related malignancies or cardiovascular diseases [4]. However, due to the slow progression of chronic hepatitis C, such trends may be slow to emerge. Some studies predict a rise in liver-related deaths to continue for another decade [5, 6], meanwhile the number of HCV-related deaths are stable or increasing in many settings [7]. Various studies have analysed mortality among HCV-infected persons. In the United States (US), several studies have shown that HCV-related deaths disproportionally affect persons born between 1945 and 1965 [8, 9]. Both a comparison between the Chronic Hepatitis Cohort Study and the official death certificates in the US [9], and a comparison between the Swiss Hepatitis C Cohort Study (SCCS) and the death certificates from the Swiss Federal Statistical Office (SFSO) [7] showed that underreporting of HCV infection on death certificates is quite common. In both the US and Switzerland, HCVrelated mortality increased significantly between the late 1990s and the early 2000s, whereas human immunodeficiency virus (HIV)-related mortality decreased, and hepatitis B virus (HBV)-related mortality remained relatively stable [7, 8]. In New South Wales, Australia, HCV notifications were linked to the death registry [1, 2]. When comparing mortality between HCV-infected persons and the general population, both liver-related and drug-related death rates were about 15-16 times higher in Australians with HCV. In HCV mono-infected persons, liver-related deaths increased considerably with older age, and drug-related death rates were higher in younger age groups [1, 2]. In this population, liver-related mortality remained stable between 1997 and 2006, and drug-related mortality was relatively constant between 2002 and 2006 [1, 2]. More recently, a study based on the US Veterans

109

110

111

112

113

114

successful treatment substantially reduced mortality, both in the presence and absence of advanced liver disease [10, 11]. Nevertheless, few studies have analysed detailed patterns of cause-specific mortality among HCVinfected persons. We therefore investigated the risk factors and time trends for all-cause and causespecific mortality among HCV-infected persons in the SCCS. We improved mortality ascertainment by linking patients lost-to-follow-up to death certificates from the SFSO.

Methods

The Swiss Hepatitis C Cohort Study (SCCS)

The SCCS is a prospective observational cohort study, established in 2000, that continuously enrols adult patients aged ≥ 18 years in Switzerland. Only persons who are confirmed anti-HCV antibodypositive are included [12]. Eight centres are involved, including all five university hospitals in Switzerland (Basel, Bern, Geneva, Lausanne, Zurich), three large non-university hospitals (Lugano, Neuchâtel and St. Gallen) and some affiliated centres. For all persons in the SCCS, various demographic, psychosocial, clinical, laboratory and treatment data were collected via standardized questionnaires. The questionnaires were completed by physicians or study nurses, during enrolment and annual follow-up visits. The study was approved by all local ethics committees, and all persons provided written informed consent. For deceased persons, the cause of death was coded according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10) [13]. Supplementary information was also provided to specify if the death was related to HCV infection or due to an accident, a suicide or overdose/accidental poisoning.

Eligibility criteria and definitions

We included all persons enrolled before December 31^{st} 2016 (until when data on causes of death were compiled by the SFSO). We excluded those who died before January 1^{st} 2008, because the new 13-digit social security number (SSN), which was needed for the linkage, became available only in 2008. Patients were lost-to-follow-up (LTFU) if they were not seen since August 2015 and not known to have moved abroad or to have died. Sustained virologic response (SVR) was defined as an undetectable HCV RNA \geq 12 weeks after the end of antiviral treatment.

Linkage with the SFSO death registry

The SFSO has monitored causes of death in Switzerland since 1876. Causes of death are coded by the ICD-10 code based on initial, consecutive and concomitant diseases listed on the SFSO death

certificate. To complete the SCCS information on mortality, deceased and LTFU persons in the SCCS were linked to the SFSO death registry, by exact record linkage. The linkage was done for all persons who were declared LTFU or dead in the SCCS between January 1st 2008 and December 31st 2016. We used the 13-digit SSN and the date of birth for the linkage when the SSN was available. If the SSN was not available, the linkage was based on the dates of birth and death.

Coding and comparing causes of death

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

We classified the main cause of death into mutually exclusive categories (liver cancer, liver failure, nonliver cancer, cardiovascular, unnatural causes, other, unspecified) as described in Table 1. The "other" category includes all deaths with a frequency below 30 persons. Unnatural causes of death include suicide, overdose/accidental poisoning and accident. For each deceased person in the SCCS, we retained one source of information to classify the cause according to the following rules. For persons linked to the death registry, we preferentially selected ICD-10 codes from the SFSO. When this information was not available, or when the SFSO provided less specific information than the SCCS, we used the ICD-10 code from the SCCS. In case no ICD-10 code was available from the SFSO or the SCCS, we used the supplementary information from the SCCS on causes of death mentioned earlier, specifying if the death was physically related to HCV infection, or due to an accident, a suicide or an overdose/accidental poisoning. All the deceased persons who could not be classified following this procedure were defined "unspecified". Finally, the cause of death classification was reviewed by an expert clinician who corrected misclassifications of complex cases specific to HCV infection. For the deceased persons linked to the SFSO death registry, we compared the main causes of death in the SCCS and the SFSO. We measured the interrater agreement via the Kappa statistics in two ways [14]: first by directly comparing the ICD-10 codes for the main cause of death, and then by using the grouped causes of death using the groups in Table 1.

Statistical analyses

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

We calculated overall crude mortality rates and for different time periods, for both each cause of death group and all-cause mortality. We also conducted survival analysis, for which follow-up time was calculated from enrolment into the cohort or the starting date of the period of interest (baseline), to the censoring date (which was either the date of death or the last known date of being alive). When the dates of death in the SCCS and SFSO were different, we used the date of the SFSO. We calculated crude cumulative incidences for each cause of death group, accounting for competing risk (where each cause of death was a competing risk for the other causes), using the R mstate package [15]. We then used Cox Proportional Hazard regression, including time-dependent covariables [14, 15], to determine risk factors of mortality. We first analysed all-cause mortality, and then cause-specific mortality, for each of the causes of death (except for "other" and "unspecified"). Analyses were adjusted for sex, baseline age (as a continuous variable with restricted cubic splines [18]), fibrosis score (F1 to F4), history of injection drug use (IDU) (ever, never), and treatment status (never treated, treated with SVR, treated without SVR). For all-cause mortality, we also accounted for the treatment history (never treated, ever treated and received DAA, ever treated but never received DAA). Due to the limited number of deceased patients who received DAA, we could not add this co-variable in the causespecific analysis. To determine the fibrosis score, we combined the information from liver biopsies, FibroScanTM analyses, and any reported cirrhosis during follow-up. Liver stiffness assessed by FibroScan[™] was converted to Metavir scores (F1: <7.5 kPa, F2: ≥ 7.5 to < 9.5 kPa, F3: ≥ 9.5 to < 12.5 kPa, and F4: ≥ 12.5 kPa) and reported cirrhosis was translated into a Metavir fibrosis score of 4. We made no assumption on the possible evolution of fibrosis over time, and carried the values forward until the next measurement or until the end of the study. We used multiple imputation by chained equations (R mice package [19]) to impute missing values of time-dependent covariables (see details in Appendix 1). For sensitivity analysis, we recalculated the Cox Proportional Hazard models without multiple imputation, excluding all the persons for whom information on treatment type and outcome, fibrosis score, and history of IDU was incomplete at any time over the period of interest.

Results

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Linkage SCCS - SFSO death registry A total of 4,700 SCCS participants were followed between January 1st 2008 and December 31st 2016, with 471 of them reported to be deceased. The SSN was available for 66.0% (311 of 471) of persons and in the case where the SSN was not available (30.4% of persons, 143 of 471) the date of death was known. In addition, 245 of the followed persons were LTFU and 87.3% (n=214) of them had a SSN. Overall, 361 of the 471 deceased patients and 7 of the LTFU patients could be linked to the SFSO death registry. Figure 1 summarizes the flow chart of the linkage between the SCCS and the SFSO. Among the linked persons in the SCCS, the reported date of death was identical for 298 persons, was different for 54 (for 11 the difference was ± 1 day), and was missing for 16 persons (including the 7 persons LTFU who could be linked). Characteristics of persons in the SCCS After linkage between the SCCS and the SFSO death registry, date of death was known for 474 persons and remained unknown for 4 persons. The median duration of follow-up per patient was 6.5 years (IQR: 2.2 - 9.0). During a total of 26,114 person-years (pyrs) of follow-up, the overall mortality rate was 18.3/1,000 pyrs (95%CI: 16.7 - 20.0). Table 2 shows the baseline characteristics of all the SCCS persons who were included and of deceased persons who could or could not be linked to the death registry. Persons were mostly male (61.7%), Swiss nationals (73.5%), and their median age at start of follow-up was 47.5 years (IQR: 40.6 - 55.1). The majority (54.9%) had a history of IDU, 38.8% had received antiviral treatment, and 17.6% were cirrhotic. Deceased persons who could or could not be linked to the death registry had similar characteristics (<u>Table 2</u>).

Comparison between causes of death in the SCCS and in the SFSO death registry

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

2008-2016.

Of the 368 deceased persons who were linked to the death registry, the main cause of death was available from both the SCCS and the SFSO for 249 persons (67,7%), and for 227 (91,1%) of these 249 persons ICD-10 codes were provided in the SCCS. When comparing the causes of death using the ICD-10 codes, the Kappa statistic for interrater agreement was 0.14 (for 40 of 227 cases the codes were identical). If we used the grouped causes of death, the Kappa statistics increased to 0.45 (in 138 of 249 cases the causes were identical), demonstrating that the agreement was weak for both approaches. Time trends in all-cause and cause-specific mortality among the persons in the SCCS Liver failure was the leading cause of death, with a crude death rate of 4.4/1000 pyrs (95% CI: 3.6 -5.2), followed by liver cancer (3.4/1000 pyrs, CI 2.8 - 4.2), non-liver cancer (2.8/1000 pyrs, CI 2.2 - 3.4), unnatural causes (2.5/1000 p-years, CI 2.0 - 3.1), other causes (2.3/1000 pyrs, CI 1.8 - 2.9), and cardiovascular causes (1.3/1000 pyrs, CI 0.9 - 1.7). For 10% (n = 46) of the 478 deceased persons the main cause of death was unknown. Figure 2 shows the evolution of crude mortality rates for all-cause mortality, liver failure and liver cancer mortality over the years. Similar curves for all the considered causes of death can be found in Appendix 2. Before 2014, the leading cause of death was liver failure, followed by liver cancer and nonliver cancer. In contrast, after 2014, when DAA became more widely available in Switzerland, liver cancer became the leading cause of death, followed by liver failure and non-liver cancer. Figure 3 shows the cumulative incidence of causes of death over time. The overall probability of dying from any cause increased from 1.5% after one year of follow-up to 13.8% after eight years. While liver failure remained the most common cause of death throughout the follow-up period, liver cancer increased in relative proportion from year 6 onwards. Table 3 shows the risk factors for all-cause and cause-specific mortality in the SCCS over the period

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

For all-cause mortality, the risk of death was increased for men, older persons, those with a high fibrosis stage and those with a history of IDU. Compared to persons who were never treated, the risk of death was lower for treated persons who reached SVR after receiving interferon (IFN)-based treatment (HR 0.33, 95% CI 0.24 - 0.45), and even slightly lower for treated persons who reached SVR after receiving DAA (HR 0.23, 95% CI 0.08 - 0.63). In contrast, treated persons who did not achieve SVR had a comparable risk of death to those who were never treated, irrespective of type of treatment. Older persons and those with fibrosis score ≥ F3 were at higher risk of dying from liver failure than younger persons and those with fibrosis score ≤ F2. Baseline treatment status was associated with mortality due to liver failure, with a pronounced protective effect for treated persons with SVR, but no reduction in risk for persons treated without SVR. For liver cancer, the risk of death was higher for older persons, as reported previously by other studies [20], and those with a high fibrosis stage. Having a history of IDU had little impact on liver cancer mortality. Compared to never treated persons, the risk of dying decreased for treated persons with SVR, but not for treated persons without SVR. The risk of dying from non-liver cancer was higher for older persons than for younger persons. Although there was no significant association between non-liver cancer mortality and treatment status, nor with baseline fibrosis score, persons with a history of IDU were more at risk than persons without a history of IDU. Having ever used injectable drugs was associated with an increased risk of dying from unnatural causes. In addition, persons aged 20 years were more at risk than persons aged 40 years or older, as well as persons with a fibrosis score \geq F3 compared to those with fibrosis score \leq F2. There was no association between unnatural causes of death and treatment status.

- 273 Results from the sensitivity analysis were similar to the main analysis for all-cause mortality, but there
- 274 were some notable differences for cause-specific mortality (Appendix 3).

Discussion

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

Based on the SCCS data, we investigated time trends and risk factors of all-cause and cause-specific mortality among HCV-infected persons in Switzerland. The linkage of the LTFU persons to the death registry did not significantly increase the number of deaths. However the proportion of unknown causes of death decreased substantially from 42% without linkage to 10% with linkage. The leading causes of death changed over time, with a substantial increase in the proportion of deaths related to liver cancer. Two factors probably explain this change: the risk of dying from liver disease increased as people became older; and ascertainment of cause of death may have improved over time. Indeed, the proportion of unspecified causes of death decreased from 13% in 2008-2013 to 4% in 2014-2016, reflecting the better linkage in the latter years (92% of deceased persons could be linked in 2014-2016, compared to 67% in 2008-2013). Similarly to other studies [7], we found that mortality remained stable among HCV-infected persons in Switzerland over the past few years. The expected decrease in mortality due to DAA is therefore not occurring, or more probably not yet observable. The risk of death was lower for women, younger persons, persons with lower fibrosis score, persons without a history of IDU, and treated persons who reached SVR, with a first indication of a more positive effect with DAA compared to IFN-based treatments. However, in contrast to some other studies, we found little evidence that being treated with subsequent treatment failure had a protective effect compared to remaining untreated [19, 20]. For both liver failure and liver cancer, the risk of dying was significantly associated with treatment, with a lower risk for treated persons with SVR than for treated persons without SVR or for untreated persons. As data for wider use of DAA was only available for three years (2014 - 2016), we were not able to evaluate the difference between successful IFN treatment and successful DAA treatment with respect to liver-related mortality. Furthermore, in the early DAA era, the reimbursement of DAA by health insurances was limited to persons with advanced fibrosis (Metavir stages F3 or F4). By mid-2016, patients with Metavir score F2 were also treated [21, 22]. The limitation based on fibrosis stage

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

was relaxed progressively between July and October 2017, when all patients were treated, although the prescription of DAA remained restricted to specialists. Having a history of IDU was an important risk factor for death from non-liver cancer and unnatural causes of death, explained by the inclusion of overdose/accidental poisoning in this category. Persons who inject drugs (PWID) are a key subgroup of HCV-infected persons in Switzerland and other highincome countries, where the majority of HCV infections occurred via injection of drugs [23, 24]. Despite the implementation of the four-pillar strategy [27], a national drug policy in Switzerland since 1994, additional obstacles exist for HCV treatment among PWID both from treatment providers and from patients [27]. This results in some HCV-infected PWID entered care relatively late, at an advanced fibrosis stage. The proportion of infected PWID who received anti-HCV treatments increased only slightly from 51% in the years 2008-2013 to 58% in the years 2014-2016. The delay in treatment initiation probably decreased, and even PWID who enter care late are more likely to reach favourable outcomes with DAA. However, persons with a history of IDU now have a higher risk of dying from nonliver cancer, potentially related to their addiction and to additional risk factors that are common among PWID, such as smoking or excessive alcohol consumption. Differences between causes of death reported in the SFSO death registry and the SCCS can be partly explained by different coding practices. Detailed analysis of the discrepant entries revealed that for 19% of cases where the cause of death was coded as "other" in the SCCS, it was coded as "non-liver cancer", "unnatural cause", or "cardiovascular disease" in the SFSO. The main focus of the SCCS was likely to identify all HCV-related deaths, and there was less emphasis to record the exact cause of death. For 21% of SCCS entries, cause of death was "liver failure" in one dataset and "liver cancer" in the other, two causes that are relatively similar. Overall, clear discrepancies in the causes of death recorded in the SCCS and the SFSO existed in only 21% of cases (Appendix 4).

To our knowledge, this is one of the first studies investigating detailed risk factors and time trends of cause-specific mortality among HCV-infected persons. Due to the linkage with the death registry, we significantly improved information on causes of death. By accounting for competing risks, by including age as a continuous covariate (and not categorizing it arbitrarily), and by adjusting models for time-dependent covariables, we could improve the accuracy of our analysis.

A limitation of this study was the unavailability of complete data relating to fibrosis stage evolution. Due to this, we made no assumption on the evolution of fibrosis over time, and used multiple imputation to impute missing values, which may compromise the robustness of our analysis. We did a sensitivity analysis, using complete cases only. In this analysis, the number of persons for the cause-specific analysis was relatively limited and results may therefore be less reliable.

In conclusion, although mortality did not, or did not yet decrease with DAA, we found that causes of death changed over time. With the wider use of DAA, irrespective of fibrosis stage, it is likely that liver-related mortality will continue to decline in the future. Continuous monitoring of mortality and causes of death will therefore remain important to evaluate the long-term effect of DAA and to develop effective interventions.

Acknowledgments

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

The Swiss Hepatitis C Cohort Study group comprises Francesco Negro, Laurent Kaiser (Geneva); Markus Heim, Hans Hirsch (Basel); Nasser Semmo, Franziska Suter (Bern); Darius Moradpour, Vincent Aubert (Lausanne); Hans H. Siegrist (La Chaux-de-Fonds); Andreas Cerny, Gladys Martinetti Lucchini (Lugano); Olivier Clerc (Neuchâtel); David Semela, Patrick Schmid, Günter Dollenmaier (St. Gallen); Beat Müllhaupt, Elsbeth Probst-Müller (Zürich); Pascal Benkert, Thomas Fabbro, Marielle Rutquist, Constantin Sluka (Basel Clinical Trial Unit). We gratefully thank the SCCS study nurses: Ulrike Schnee-Lach (Basel); Kathrin Husi, Alice Gilg (Bern); Nicole Eicher, Fabio Cassano (Geneva); Adeline Mathieu, Maribelle Herranz (Lausanne); Claudia Dibartolomeo (Lugano); Marielle Grosjean (Neuchâtel); Patrizia Künzler-Heule, Roman Stillhard, Michelle Grahornig, Simone Kessler (St. Gallen); Barbara Brunner- Geissmann, Andrea Zumbühl (Zürich). We thank the Swiss Federal Statistical Office for providing mortality data and for their support, which made this study possible. We thank Danny Sheath and Rachel Esra for the editorial support.

References

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

[1] J. Amin, M. G. Law, M. Bartlett, J. M. Kaldor, and G. J. Dore, 'Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study', The Lancet, vol. 368, no. 9539, pp. 938-945, Sep. 2006. [2] S. R. Walter et al., 'Trends in mortality after diagnosis of hepatitis B or C infection: 1992– 2006', J. Hepatol., vol. 54, no. 5, pp. 879–886, May 2011. [3] F. Carrat et al., 'Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study', The Lancet, vol. 0, no. 0, Feb. 2019. [4] P. Cacoub et al., 'Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients', Am. Heart J., vol. 198, pp. 4–17, Apr. 2018. [5] M.-H. Lee et al., 'Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study', J. Infect. Dis., vol. 206, no. 4, pp. 469-477, Aug. 2012. [6] H. Razavi et al., 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', J. Viral Hepat., vol. 21, no. s1, pp. 34–59, 2014. [7] O. Keiser et al., 'Trends in hepatitis C-related mortality in Switzerland', J. Viral Hepat., vol. 25, no. 2, pp. 152–160, Feb. 2018. [8] K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, 'The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007',

Ann. Intern. Med., vol. 156, no. 4, p. 271, Feb. 2012.

- [9] R. Mahajan et al., 'Mortality Among Persons in Care With Hepatitis C Virus Infection: The 387
- Chronic Hepatitis Cohort Study (CHeCS), 2006–2010', Clin. Infect. Dis., vol. 58, no. 8, pp. 388
- 1055-1061, Apr. 2014. 389
- L. I. Backus, P. S. Belperio, T. A. Shahoumian, and L. A. Mole, 'Direct-acting antiviral 390 [10]
- 391 sustained virologic response: Impact on mortality in patients without advanced liver
- disease', Hepatology, vol. 68, no. 3, pp. 827–838, 2018. 392
- 393 [11] L. I. Backus, P. S. Belperio, T. A. Shahoumian, and L. A. Mole, 'Impact of Sustained
- 394 Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with
- Advanced Liver Disease', Hepatology, vol. 69, no. 2, pp. 487–497, 2019. 395
- L. Prasad, V. M. Spicher, M. Zwahlen, M. Rickenbach, B. Helbling, and F. Negro, 396 [12]
- 'Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS)', Int. J. Epidemiol., vol. 36, no. 397
- 4, pp. 731-737, Aug. 2007. 398
- 399 [13] 'ICD-10 Version: 2016'. [Online]. Available: https://icd.who.int/browse10/2016/en.
- 400 [Accessed: 29-Nov-2019].
- M. L. McHugh, 'Interrater reliability: the kappa statistic', Biochem. Medica, vol. 22, 401 [14]
- 402 no. 3, pp. 276–282, Oct. 2012.
- 403 [15] H. Putter, 'Tutorial in biostatistics: Competing risks and multi-state models Analyses
- using the mstate package', p. 43. 404
- L. D. Fisher and D. Y. Lin, 'Time-Dependent Covariates in the Cox Proportional-405 [16]
- Hazards Regression Model', Annu. Rev. Public Health, vol. 20, no. 1, pp. 145–157, 1999. 406
- T. Therneau, C. Crowson, and E. Atkinson, 'Using Time Dependent Covariates and 407 [17]
- Time Dependent Coefficients in the Cox Model', p. 27. 408
- 409 [18] B. E. Shepherd and P. F. Rebeiro, 'Assessing and interpreting the association between
- 410 continuous covariates and outcomes in observational studies of HIV using splines', J.
- Acquir. Immune Defic. Syndr. 1999, vol. 74, no. 3, pp. e60-e63, Mar. 2017. 411

412 [19] S. van Buuren and K. Groothuis-Oudshoorn, 'mice: Multivariate Imputation by 413 Chained Equations in R', J. Stat. Softw., vol. 45, no. 1, pp. 1–67, Dec. 2011. J.-F. Dufour, A. Bordoni, and M. Lorez, 'Trends in Hepatic Cancer Survival in 414 Switzerland', Bull. Suisse Cancer, vol. éd. Mars, no. 1, pp. 46–50, 2014. 415 Y. Wen, Y. X. Zheng, and D. M. Tan, 'A Comprehensive Long-Term Prognosis of 416 [21] Chronic Hepatitis C Patients With Antiviral Therapy: A Meta-Analysis of Studies From 417 2008 to 2014', Hepat. Mon., vol. 15, no. 5, May 2015. 418 M. Lu et al., 'Hepatitis C treatment failure is associated with increased risk of 419 [22] hepatocellular carcinoma', J. Viral Hepat., vol. 23, no. 9, pp. 718-729, Sep. 2016. 420 J. Fehr, D. Moradpour, A. Rauch, and B. Müllhaupt, 'Treatment of Chronic Hepatitis C 421 [23] - September 2016 Update SASL-SSI Expert Opinion Statement', p. 10. 422 423 [24] N. Vernaz et al., 'A buyers' club to improve access to hepatitis C treatment for 424 vulnerable populations', Swiss Med. Wkly., vol. 148, no. 3334, Aug. 2018. F. Cominetti, T. Simonson, F. Dubois-Arber, J.-P. Gervasoni, M. Schaub, and M. 425 [25] Monnat, 'Analyse de la situation de l' hépatite C chez les usagers de drogue en 426 427 Suisse', 2015... C. Zahnd, M. Brezzi, B. Bertisch, F. Giudici, and O. Keiser, 'Analyse de situation des 428 [26] 429 hépatites B et C en Suisse'. Sur mandat de l'Office fédéral de la santé publique (OFSP), 2017. 430 F. Negro and L. Maistat, 'Access to hepatitis C treatment for patients in drug 431 [27] substitution programmes: the fight is far from over', Swiss Med. Wkly., vol. 147, no. 432

4950, Dec. 2017.

433

Tables

Table 1: Categories of causes of death

Death cause group	Eligibility criteria
Liver failure (other than liver cancer)	Selected ICD-10 codes:
	B15 - B19 (viral hepatitis)
	B94.2 (sequelae of viral hepatitis)
	K70 (alcoholic liver disease)
	K71 - K77 (toxic/chronic/other liver disease)
	T86.4 (liver transplant failure and rejection)
	Z94.4 (liver transplant status)
	OR
	Death identified as physically related to HCV
	infection according to information obtained at
	or after a SCCS visit
Liver cancer	Selected ICD-10 code: C22
Non-liver cancer	Selected ICD-10 codes:
	C00 - C21, C23 - C97 (all malignant neoplasms
	except liver cancer, including leukaemia)
	D00 – D48 (all in-situ, benign and unknown
	neoplasms)
Unnatural cause	Selected ICD-10 codes:
	S00 - T88 except T86.4 (injury, poisoning and
	certain other consequences of external cause)
	V01 – Y98 (external causes of morbidity and
	mortality)
	Z92 – Z99 except Z94.4 (health-service-related
	factor)
	OR
	Death identified as due to accident, suicide or
	overdose of narcotics according to the SCCS
Cardiovascular	Selected ICD-10 codes:
0.1	100 – 199 (diseases of the circulatory system)
Other	All the deaths with selected ICD-10 code not
	entering any of the criteria described above
Unspecified	No selected ICD-10 code and no complementary
	information from the SCCS

Table 2: Characteristics of study participants at enrolment and causes of death in the Swiss **Hepatitis C Cohort Study**

440

441 442

443

444

445

P-values from Kruskal-Wallis rank sum test for continuous variables, and Chi-squared test for categorical variables are shown.

		All	Death	Death linked	Death not linked	P-value linked VS not linked
		N=4700	N=478	N=368	N=110	
Sex						P = 0.86
	Male	2901 (61.72)	338 (70.71)	259 (70.38)	79 (71.82)	
	Female	1799 (38.28)	140 (29.29)	109 (29.62)	31 (28.18)	
Nationality						P = 0.28
	Swiss	3456 (73.53)	372 (77.82)	291 (79.08)	81 (73.64)	
	Other	1235 (26.28)	106 (22.18)	77 (20.92)	29 (26.36)	
	Unknown	9 (0.19)	X	X	Χ	
Age at start (yr)		47.5 (40.6 – 55.1)	51.8 (44.5 – 60)	52 (45 – 60.1)	50.9 (43.3 – 57.2)	P = 0.31
Age at death census (yr)		53.5 (46.4 – 60.5)	56 (48.5 – 64.7)	56.3 (50.4 – 65.3)	53.6 (46.1 – 60)	P = 0.01
me from start to death census (yr)		6.5 (2.2 – 9)	4 (2 – 6.5)	4.9 (2.9 – 6.8)	1.6 (0.6 – 3.5)	P < 0.001
Treatment before start						P = NA
	No	2910 (61.91)	263 (55.02)	194 (52.72)	69 (62.73)	
	DAA (IFN-free)	33 (0.7)	X	X	X	
	IFN-based	1757 (37.38)	215 (44.98)	174 (47.28)	41 (37.27)	
IDU before start						P = 0.78
	Never	1780 (37.87)	182 (38.08)	142 (38.59)	40 (36.36)	
	Ever	2578 (54.85)	263 (55.02)	201 (54.62)	62 (56.36)	
	Unknown	342 (7.28)	33 (6.9)	25 (6.79)	8 (7.27)	
Fibrosis score at start						P = 0.42
	F0, F1 or F2	2538 (54)	160 (33.47)	123 (33.42)	37 (33.64)	
	F3 or F4	1261 (26.83)	229 (47.91)	185 (50.27)	44 (40)	
	Unknown	901 (19.17)	89 (18.62)	60 (16.3)	29 (26.36)	
Treatment status before start						P = 0.12
	Never treated	2910 (61.91)	263 (55.02)	194 (52.72)	69 (62.73)	
	Treated with SVR	693 (14.74)	44 (9.21)	35 (9.51)	9 (8.18)	
	Treated with failure	941 (20.02)	144 (30.13)	119 (32.34)	25 (22.73)	
	Treated, outcome unknown	156 (3.32)	27 (5.65)	20 (5.43)	7 (6.36)	
BMI at start		24.1 (21.6 – 27.1)	24.9 (21.6 – 28.5)	24.8 (21.6 – 28.4)	25.7 (21.8 – 30.8)	P = 0.26
HIV co-infection at start						P = 0.24
	No	3204 (68.17)	326 (68.2)	252 (68.48)	74 (67.27)	
	Yes	258 (5.49)	51 (10.67)	35 (9.51)	16 (14.55)	
	Unknown	1238 (26.34)	101 (21.13)	81 (22.01)	20 (18.18)	
Cirrhosis at start						P = 0.84
	No	3259 (69.34)	213 (44.56)	165 (44.84)	48 (43.64)	
	Yes	828 (17.62)	207 (43.31)	163 (44.29)	44 (40)	
	Unknown	613 (13.04)	58 (12.13)	40 (10.87)	18 (16.36)	
Diabetes mellitus at start						P = 0.01
	No	4019 (85.51)	336 (70.29)	274 (74.46)	62 (56.36)	
	Yes	275 (5.85)	52 (10.88)	33 (8.97)	19 (17.27)	
	Unknown	406 (8.64)	90 (18.83)	61 (16.58)	29 (26.36)	
Alcohol consumption at start						P = 0.11
	Light	2952 (62.81)	268 (56.07)	199 (54.08)	69 (62.73)	
	Former	348 (7.4)	43 (9)	38 (10.33)	5 (4.55)	
	Heavy	749 (15.94)	111 (23.22)	91 (24.73)	20 (18.18)	
	Moderate	563 (11.98)	46 (9.62)	34 (9.24)	12 (10.91)	
	Unknown	88 (1.87)	10 (2.09)	6 (1.63)	4 (3.64)	
Cause of death						P = NA
	Cardiovascular	33 (0.7)	33 (6.9)	26 (7.07)	7 (6.36)	
	Liver cancer	89 (1.89)	89 (18.62)	84 (22.83)	5 (4.55)	
	Liver failure	114 (2.43)	114 (23.85)	99 (26.9)	15 (13.64)	
	Non-liver cancer	72 (1.53)	72 (15.06)	65 (17.66)	7 (6.36)	
	Other	59 (1.26)	59 (12.34)	41 (11.14)	18 (16.36)	
	Unnatural	65 (1.38)	65 (13.6)	53 (14.4)	12 (10.91)	

Table 3: Estimates of the effect of gender, age, treatment, fibrosis stage and IDU on mortality, from Cox regression models, accounting for competing risk

A) For all-cause mortality; B) For cause-specific mortality

۸۱		Total: 4700 persons	All-cause		
Α,		Total: 4700 persons	(478 deaths)		
	Sex		P < 0.001		
		Male	1		
		Female	0.68 (0.56 – 0.84)		
	Age at start (yr)		P < 0.001		
		20	0.59 (0.37 – 0.96)		
		40	1		
		60	2.52 (2.04 - 3.11)		
	Treatment status		P < 0.001		
		Never treated	1		
		Treated with DAA, SVR	0.23 (0.08 – 0.63)		
		Treated with DAA, failure	0.94 (0.33 – 2.66)		
		Treated with IFN, SVR	0.33 (0.24 – 0.45)		
		Treated with IFN, failure	0.87 (0.71 – 1.07)		
	Fibrosis score		P < 0.001		
		F0, F1 or F2	1		
		F3 or F4	3.57 (2.9 – 4.38)		
	IDU		P < 0.001		
		Never	1		
		Ever	2.01 (1.57 – 2.58)		

	Total: 4700 persons	Liver failure	Liver cancer	Non-liver cancer	Cardiovascular	Unnatural cause
	iotal. 4700 persons	(114 deaths, 23.8%)	(89 deaths, 18.6%)	(72 deaths, 15.1%)	(33 deaths, 6.9%)	(65 deaths, 13.6%)
Sex		P = 0.15	P = 0.09	P = 0.074	P = 0.041	P = 0.18
	Male	1	1	1	1	1
	Female	0.73 (0.48 - 1.12)	0.66 (0.41 - 1.07)	0.61 (0.36 - 1.05)	0.44 (0.2 - 0.97)	0.68 (0.39 - 1.19)
Age at start (yr)		P = 0.016	P < 0.001	P < 0.001	P < 0.001	P = 0.044
	20	0.26 (0.08 - 0.89)	0.08 (0.01 - 0.62)	0.05 (0.01 - 0.28)	0.65 (0.08 - 5.62)	2.92 (1.23 - 6.96)
	40	1	1	1	1	1
	60	2.1 (1.27 - 3.48)	6.32 (2.74 – 14.57)	8.5 (4.03 – 17.92)	5.23 (2.05 – 13.31)	1.04 (0.59 – 1.84)
Treatment status		P < 0.001	P < 0.001	P = 0.29	P = 0.16	P = 0.12
	Never treated	1	1	1	1	1
	Treated with SVR	0.18 (0.08 - 0.38)	0.32 (0.15 – 0.7)	0.6 (0.32 - 1.14)	0.39 (0.14 - 1.11)	0.47 (0.23 - 0.97)
	Treated with failure	0.8 (0.53 – 1.2)	1.37 (0.83 – 2.26)	0.83 (0.46 - 1.5)	0.62 (0.26 - 1.45)	0.92 (0.5 – 1.7)
Fibrosis score		P < 0.001	P < 0.001	P = 0.11	P = 0.0064	P = 0.024
	F0, F1 or F2	1	1	1	1	1
	F3 or F4	12.67 (7.22 – 22.24)	13.75 (6.49 – 29.17)	1.51 (0.91 – 2.51)	2.91 (1.35 - 6.27)	1.96 (1.09 – 3.5)
IDU		P = 0.25	P = 0.19	P < 0.001	P = 0.2	P = 0.0013
	Never	1	1	1	1	1
	Ever	1.32 (0.82 - 2.11)	1.47 (0.83 - 2.62)	3.33 (1.68 - 6.6)	2.01 (0.7 - 5.78)	3.57 (1.64 – 7.77)

Figure legends

Fig. 1. Flow chart illustrating the linkage between the Swiss Hepatitis C Cohort Study (SCCS) and the death registry of the Swiss Federal Office of Statistics (SFSO)

Fig. 2. Crude mortality rates over the years for all-cause mortality, liver failure and liver cancer mortality in the Swiss Hepatitis C Cohort Study

Fig. 3. Cumulative incidence of different causes of death since registration into the Swiss Hepatitis C cohort study (causes of death are in the same order in the legend and on the plot)

Figures

Fig. 1.




Fig. 2





Fig. 3




Appendix

Appendix 1: Details on the multiple imputation

Because adding variables that are not part of the analysis can improve the imputation, we added the following baseline explanatory variables: body mass index (BMI), HIV co-infection, cirrhotic status, diabetes comorbidity, alcohol consumption (light/no drinker if average consumption ≤ 20g/day, moderate drinker if average consumption between 21 and 40g/day, excessive drinker if average consumption > 40g/day, and former drinker if ever drank more than 40g/day but is now a light or moderate drinker). Furthermore, the outcome was also included in the imputation. We ran the model on 20 imputed datasets for each analysis and combined the estimates with Rubin's rule.

Appendix 2: Time trends in mortality rates (with 95% confidence intervals), per cause of death The x-axis corresponds to the year of death

484



Appendix 3: Hazard ratios from Cox regression models, accounting for competing risk, excluding persons with missing information (sensitivity analysis)

A) For all-cause mortality; B) For cause-specific mortality

B)

		Total: 4700 persons	All-cause		
			(294 deaths)		
	Sex		P < 0.001		
		Male	1		
l		Female	0.63 (0.49 - 0.82)		
I	Age at start (yr)		P < 0.001		
		20	0.43 (0.22 – 0.85)		
		40	1		
		60	2.81 (2.09 - 3.78)		
Treatment status			P < 0.001		
		Never treated	1		
		Treated with DAA, SVR	0.13 (0.03 – 0.52)		
		Treated with DAA, failure	0.3 (0.04 – 2.19)		
		Treated with IFN, SVR	0.32 (0.23 - 0.46)		
		Treated with IFN, failure	0.78 (0.59 - 1.01)		
	Fibrosis score		P < 0.001		
		F0, F1 or F2	1		
		F3 or F4	3.48 (2.7 - 4.49)		
	IDU		P < 0.001		
		Never	1		
		Ever	1.98 (1.46 – 2.68)		

	Total: 2719 persons	Liver failure	Liver cancer	Non-liver cancer	Cardiovascular	Unnatural cause
	Total: 27 19 persons	(80 deaths, 27.2%)	(60 deaths, 20.4%)	(47 deaths, 16%)	(20 deaths, 6.8%)	(28 deaths, 9.5%)
Sex		P = 0.66	P = 0.0075	P = 0.068	P = 0.026	P = 0.53
	Male	1	1	1	1	1
	Female	0.9 (0.55 - 1.46)	0.42 (0.22 - 0.79)	0.53 (0.27 - 1.05)	0.28 (0.09 - 0.86)	0.77 (0.33 - 1.76)
Age at start (yr)		P = 0.12	P < 0.001	P < 0.001	P < 0.001	P = 0.72
	20	0.25 (0.06 - 1.16)	0.16 (0.02 - 1.61)	0.15 (0.02 - 1.01)	0.75 (0.05 – 11.65)	1.69 (0.38 - 7.54)
	40	1	1	1	1	1
	60	1.95 (1.03 – 3.7)	5.51 (2.06 - 14.72)	6.75 (2.94 – 15.47)	3.87 (1.17 – 12.84)	0.77 (0.28 - 2.13)
Treatment status		P < 0.001	P < 0.001	P = 0.63	P = 0.18	P = 0.74
	Never treated	1	1	1	1	1
	Treated with SVR	0.09 (0.03 - 0.23)	0.38 (0.15 - 0.95)	0.7 (0.34 - 1.45)	0.44 (0.14 - 1.35)	0.7 (0.27 - 1.8)
	Treated with failure	0.53 (0.33 - 0.86)	1.71 (0.87 – 3.37)	0.87 (0.43 – 1.77)	0.39 (0.13 - 1.22)	0.93 (0.37 – 2.38)
Fibrosis score		P < 0.001	P < 0.001	P = 0.85	P = 0.14	P = 0.21
	F0, F1 or F2	1	1	1	1	1
	F3 or F4	18.28 (8.9 – 37.58)	10.84 (4.84 – 24.26)	1.06 (0.57 - 1.95)	2 (0.79 - 5.04)	1.69 (0.74 - 3.83)
IDU		P = 0.53	P = 0.12	P < 0.001	P = 0.8	P = 0.02
	Never	1	1	1	1	1
	Ever	1.19 (0.69 – 2.04)	1.72 (0.88 - 3.4)	4.39 (1.9 - 10.14)	0.84 (0.23 - 3.14)	3.75 (1.23 – 11.42

Appendix 4: Comparison between SCCS and SFSO death cause groups

495

SCCS / SFSO	Cardiovascular	Liver cancer	Liver failure	Non-liver cancer	Other	Unnatural cause
Cardiovascular	9	2	9	3	3	1
Liver cancer	0	34	1	2	0	0
Liver failure	3	22	34	2	7	1
Non-liver cancer	0	2	1	33	0	0
Other	6	6	21	12	14	3
Overdose	1	0	0	0	1	5
Unnatural cause	0	0	0	0	2	9
Unspecified	10	13	24	15	29	28